keyword
MENU ▼
Read by QxMD icon Read
search

L-DOPA rodent

keyword
https://www.readbyqxmd.com/read/27764702/contribution-of-the-nitric-oxide-donor-molsidomine-and-the-antiparkinsonian-drug-l-dopa-to-the-modulation-of-the-blood-pressure-in-unilaterally-6-ohda-lesioned-rats
#1
Elżbieta Lorenc-Koci, Anna Czarnecka, Kinga Kamińska, Joanna Knutelska, Małgorzata Zygmunt, Magdalena Dudek
BACKGROUND: Interaction between dopaminergic and nitrergic neurotransmission in the brain plays a crucial role in the control of motor function and in the regulation of blood pressure (BP). In Parkinson's disease (PD), dopaminergic denervation of the striatum leads to disturbances in the nitrergic system in the basal ganglia. Recently, it has been demonstrated that addition of a low dose of the nitric oxide donor molsidomine to l-DOPA therapy improves dopaminergic neurotransmission in the denervated nigrostriatal system and weakens dyskinesias in rodent models of the disease...
September 28, 2016: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/27733830/cannabidiol-prevents-motor-and-cognitive-impairments-induced-by-reserpine-in-rats
#2
Fernanda F Peres, Raquel Levin, Mayra A Suiama, Mariana C Diana, Douglas A Gouvêa, Valéria Almeida, Camila M Santos, Lisandro Lungato, Antônio W Zuardi, Jaime E C Hallak, José A Crippa, D'Almeida Vânia, Regina H Silva, Vanessa C Abílio
Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that presents antipsychotic, anxiolytic, anti-inflammatory, and neuroprotective effects. In Parkinson's disease patients, CBD is able to attenuate the psychotic symptoms induced by L-DOPA and to improve quality of life. Repeated administration of reserpine in rodents induces motor impairments that are accompanied by cognitive deficits, and has been applied to model both tardive dyskinesia and Parkinson's disease. The present study investigated whether CBD administration would attenuate reserpine-induced motor and cognitive impairments in rats...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27618286/l-dopa-induced-dyskinesia-in-parkinson-s-disease-are-neuroinflammation-and-astrocytes-key-elements
#3
Elaine Del-Bel, Mariza Bortolanza, Maurício Dos-Santos-Pereira, Keila Bariotto, Rita Raisman-Vozari
Inflammation in Parkinson's disease (PD) is a new concept that has gained ground due to the potential of mitigating dopaminergic neuron death by decreasing inflammation. The solution to this question is likely to be complex. We propose here that the significance of inflammation in PD may go beyond the nigral cell death. The pathological process that underlies PD requires years to reach its full extent. A growing body of evidence has been accumulated on the presence of multiple inflammatory signs in the brain of PD patients even in very late stages of the disease...
December 2016: Synapse
https://www.readbyqxmd.com/read/27597526/validation-of-an-improved-scale-for-rating-l-dopa-induced-dyskinesia-in-the-mouse-and-effects-of-specific-dopamine-receptor-antagonists
#4
Irene Sebastianutto, Natallia Maslava, Corey R Hopkins, M Angela Cenci
Rodent models of l-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude...
September 2, 2016: Neurobiology of Disease
https://www.readbyqxmd.com/read/27596273/lack-of-antiparkinsonian-effects-of-systemic-injections-of-the-specific-t-type-calcium-channel-blocker-ml218-in-mptp-treated-monkeys
#5
Adriana Galvan, Annaelle Devergnas, Damien Pittard, Gunasingh Masilamoni, Jocelyn Vuong, J Scott Daniels, Ryan D Morrison, Craig W Lindsley, Thomas Wichmann
Dopaminergic medications ameliorate many of the motor impairments of Parkinson's disease (PD). However, parkinsonism is often only partially reversed by these drugs, and they can have significant side effects. Therefore, a need remains for novel treatments of parkinsonism. Studies in rodents and preliminary clinical evidence have shown that T-type calcium channel (TTCC) antagonists have antiparkinsonian effects. However, most of the available studies utilized nonselective agents. We now evaluated whether systemic injections of the specific TTCC blocker ML218 have antiparkinsonian effects in MPTP-treated parkinsonian Rhesus monkeys...
September 20, 2016: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/27418401/parkinsonian-monkeys-with-prior-levodopa-induced-dyskinesias-followed-by-fetal-dopamine-precursor-grafts-do-not-display-graft-induced-dyskinesias
#6
Jeffrey H Kordower, Angel Vinuela, Yaping Chu, Ole Isacson, D Eugene Redmond
Clinical trials testing the hypothesis that fetal dopamine grafts would provide antiparkinsonian benefit in patients who had already developed side-effects from their long-terms use of L-dopa revealed, in some cases, the presence of dyskinesias even in the absence of L-dopa. The form, intensity, and frequency of these dyskinesias were quite variable, but their manifestation slowed down the clinical development of cell replacement therapies. Rodent models of graft-induced dyskinesias (GIDs) have been proposed, however their accuracy in modeling GIDs has been questioned since they usually require amphetamine for their presentation...
July 15, 2016: Journal of Comparative Neurology
https://www.readbyqxmd.com/read/27378874/subthalamic-and-cortical-local-field-potentials-associated-with-pilocarpine-induced-oral-tremor-in-the-rat
#7
Lauren L Long, Samantha J Podurgiel, Aileen F Haque, Emily L Errante, James J Chrobak, John D Salamone
Tremulous jaw movements (TJMs) are rapid vertical deflections of the lower jaw that resemble chewing but are not directed at any particular stimulus. In rodents, TJMs are induced by neurochemical conditions that parallel those seen in human Parkinsonism, including neurotoxic or pharmacological depletion of striatal dopamine (DA), DA antagonism, and cholinomimetic administration. Moreover, TJMs in rodents can be attenuated by antiparkinsonian agents, including levodopa (L-DOPA), DA agonists, muscarinic antagonists, and adenosine A2A antagonists...
2016: Frontiers in Behavioral Neuroscience
https://www.readbyqxmd.com/read/27307239/dynamic-dna-methylation-regulates-levodopa-induced-dyskinesia
#8
David A Figge, Karen L Eskow Jaunarajs, David G Standaert
UNLABELLED: Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (l-DOPA) exposure in Parkinson disease patients. LID is a consequence of sustained changes in the transcriptional behavior of striatal neurons following dopaminergic stimulation. In neurons, transcriptional regulation through dynamic DNA methylation has been shown pivotal to many long-term behavioral modifications; however, its role in LID has not yet been explored...
June 15, 2016: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/27283777/l-dopa-treatment-in-mptp-mouse-model-of-parkinson-s-disease-potentiates-homocysteine-accumulation-in-substantia-nigra
#9
Nivedita Bhattacharjee, Muhammed Khairujjaman Mazumder, Rajib Paul, Amarendranath Choudhury, Sabanum Choudhury, Anupom Borah
One of the intermediates of methionine cycle, the homocysteine (Hcy), elevates in plasma of Parkinson's disease (PD) patients undergoing L-DOPA (3,4-dihydroxyphenylalanine) therapy and has been regarded as a risk factor of the disease. Several evidences pointed out that Hcy causes degeneration of dopaminergic neurons. In rodent, elevated level of Hcy in brain or infusion of the same directly into the substantia nigra (SN) potentiates dopaminergic neurodegeneration. However, the influence of L-DOPA therapy on the levels of Hcy in dopamine-rich regions of the brain (striatum and SN) of experimental models of PD is not known...
August 15, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/26903804/striatal-plasticity-in-l-dopa-and-graft-induced-dyskinesia-the-common-link
#10
REVIEW
Daniella Rylander Ottosson, Emma Lane
One of the major symptoms of the neurodegenerative condition Parkinson's disease (PD) is a slowness or loss of voluntary movement, yet frustratingly therapeutic strategies designed to restore movement can result in the development of excessive abnormal movements known as dyskinesia. These dyskinesias commonly develop as a result of pharmacotherapy in the form of L-DOPA administration, but have also been identified following deep brain stimulation (DBS) and intrastriatal cell transplantation. In the case of L-DOPA these movements can be treatment limiting, and whilst they are not long lasting or troubling following DBS, recognition of their development had a near devastating effect on the field of cell transplantation for PD...
2016: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/26871939/antidyskinetic-effect-of-a2a-and-5ht1a-1b-receptor-ligands-in-two-animal-models-of-parkinson-s-disease
#11
Annalisa Pinna, Wai Kin D Ko, Giulia Costa, Elisabetta Tronci, Camino Fidalgo, Nicola Simola, Qin Li, Mojgan Aghazadeh Tabrizi, Erwan Bezard, Manolo Carta, Micaela Morelli
BACKGROUND: The serotonin 5-HT1A/1B receptor agonist eltoprazine suppressed dyskinetic-like behavior in animal models of Parkinson's disease (PD) but simultaneously reduced levodopa (l-dopa)-induced motility. Moreover, adenosine A2A receptor antagonists, such as preladenant, significantly increased l-dopa efficacy in PD without exacerbating dyskinetic-like behavior. OBJECTIVES: We evaluated whether a combination of eltoprazine and preladenant may prevent or suppress l-dopa-induced dyskinesia, without impairing l-dopa's efficacy in relieving motor signs, in 2 PD models: unilateral 6-hydroxydopamine-lesioned rats and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys...
April 2016: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/26644333/long-term-effect-of-sub-anesthetic-ketamine-in-reducing-l-dopa-induced-dyskinesias-in-a-preclinical-model
#12
Mitchell J Bartlett, Ria M Joseph, Lindsey M LePoidevin, Kate L Parent, Nicholas D Laude, Levi B Lazarus, Michael L Heien, Miguel Estevez, Scott J Sherman, Torsten Falk
Low-dose sub-anesthetic ketamine infusion treatment has led to a long-term reduction of treatment-resistant depression and posttraumatic stress disorder (PTSD) symptom severity, as well as reduction of chronic pain states, including migraine headaches. Ketamine also is known to change oscillatory electric brain activity. One commonality between migraine headaches, depression, PTSD, Parkinson's disease (PD) and l-DOPA-induced dyskinesias (LID) is hypersynchrony of electric activity in the brain, including the basal ganglia...
January 26, 2016: Neuroscience Letters
https://www.readbyqxmd.com/read/26586558/effects-of-l-dopa-priming-on-cortical-high-beta-and-high-gamma-oscillatory-activity-in-a-rodent-model-of-parkinson-s-disease
#13
Kristin B Dupre, Ana V Cruz, Alex J McCoy, Claire Delaville, Colin M Gerber, Katherine W Eyring, Judith R Walters
Prolonged L-dopa treatment in Parkinson's disease (PD) often leads to the expression of abnormal involuntary movements known as L-dopa-induced dyskinesia. Recently, dramatic 80 Hz oscillatory local field potential (LFP) activity within the primary motor cortex has been linked to dyskinetic symptoms in a rodent model of PD and attributed to stimulation of cortical dopamine D1 receptors. To characterize the relationship between high gamma (70-110 Hz) cortical activity and the development of L-dopa-induced dyskinesia, cortical LFP and spike signals were recorded in hemiparkinsonian rats treated with L-dopa for 7 days, and dyskinesia was quantified using the abnormal involuntary movements (AIMs) scale...
February 2016: Neurobiology of Disease
https://www.readbyqxmd.com/read/26475156/perinatal-6-hydroxydopamine-to-produce-a-lifelong-model-of-severe-parkinson-s-disease
#14
John P Kostrzewa, Rose Anna Kostrzewa, Richard M Kostrzewa, Ryszard Brus, Przemysław Nowak
The classic rodent model of Parkinson's disease (PD) is produced by unilateral lesioning of pars compacta substantia nigra (SNpc) in adult rats, producing unilateral motor deficits which can be assessed by dopamine (DA) D2 receptor (D2-R) agonist induction of measurable unilateral rotations. Bilateral SNpc lesions in adult rats produce life-threatening aphagia, adipsia, and severe motor disability resembling paralysis-a PD model that is so compromised that it is seldom used. Described in this paper is a PD rodent model in which there is bilateral 99 % loss of striatal dopaminergic innervation, produced by bilateral intracerebroventricular or intracisternal 6-hydroxydopamine (6-OHDA) administration to perinatal rats...
October 17, 2015: Current Topics in Behavioral Neurosciences
https://www.readbyqxmd.com/read/26472532/nicotine-and-nicotinic-receptor-drugs-potential-for-parkinson-s-disease-and-drug-induced-movement-disorders
#15
REVIEW
Maryka Quik, Tanuja Bordia, Danhui Zhang, Xiomara A Perez
Parkinson's disease is a progressive neurodegenerative disorder associated with tremor, rigidity, and bradykinesia, as well as nonmotor symptoms including autonomic impairments, olfactory dysfunction, sleep disturbances, depression, and dementia. Although the major neurological deficit is a loss of nigrostriatal dopaminergic neurons, multiple neurotransmitters systems are compromised in Parkinson's disease. Consistent with this observation, dopamine replacement therapy dramatically improves Parkinson's disease motor symptoms...
2015: International Review of Neurobiology
https://www.readbyqxmd.com/read/26319133/nesfatin-1-localization-and-expression-in-avian-gonads-and-its-modulation-by-temporal-phase-relation-of-neural-oscillations-in-female-japanese-quail-coturnix-coturnix-japonica
#16
Somanshu Banerjee, Chandra Mohini Chaturvedi
In a search for new appetite-controlling signals, the peptide nesfatin-1, expressed in the brain and peripheral tissues of rodents and humans has been reported to regulate feeding by reducing food intake. Recently it has also been reported that nesfatin-1 might be involved in regulating the reproductive axis in fishes and mammals, but its expression and physiological role if any, is not yet known in birds. In the present study, localization and expression of nesfatin-1 was observed in the testis, ovary and shell gland of poultry species Japanese quail, Coturnix coturnix japonica...
December 1, 2015: General and Comparative Endocrinology
https://www.readbyqxmd.com/read/26297895/effect-of-parasitic-infection-on-dopamine-biosynthesis-in-dopaminergic-cells
#17
H L Martin, I Alsaady, G Howell, E Prandovszky, C Peers, P Robinson, G A McConkey
Infection by the neurotropic agent Toxoplasma gondii alters rodent behavior and can result in neuropsychiatric symptoms in humans. Little is understood regarding the effects of infection on host neural processes but alterations to dopaminergic neurotransmission are implicated. We have previously reported elevated levels of dopamine (DA) in infected dopaminergic cells however the involvement of the host enzymes and fate of the produced DA were not defined. In order to clarify the effects of infection on host DA biosynthetic enzymes and DA packaging we examined enzyme levels and activity and DA accumulation and release in T...
October 15, 2015: Neuroscience
https://www.readbyqxmd.com/read/26188284/loss-of-glutamic-acid-decarboxylase-gad67-in-striatal-neurons-expressing-the-drdr1a-dopamine-receptor-prevents-l-dopa-induced-dyskinesia-in-6-hydroxydopamine-lesioned-mice
#18
K Zhang, C Chammas, J-J Soghomonian
The objective in this study was to test the hypothesis that the GABA-synthesizing enzyme, glutamic acid decarboxylase (Gad67), expressed in striatal neurons plays a key role in dyskinesia induced by L-DOPA (LID) in a rodent model of Parkinson's disease. In light of evidence that the dopamine Drd1a receptor is densely expressed in striatal direct pathway striatal neurons while the orphan G-protein-coupled receptor Gpr88 is densely expressed in striatal direct and indirect pathway striatal neurons, we used a cre-lox strategy to produce two lines of mice that were Gad1 (Gad1 is the gene encoding for Gad67)-deficient in neurons expressing the Drd1a or the Gpr88 receptor...
September 10, 2015: Neuroscience
https://www.readbyqxmd.com/read/26013581/anti-oxidant-polydatin-piceid-protects-against-substantia-nigral-motor-degeneration-in-multiple-rodent-models-of-parkinson-s-disease
#19
Yupin Chen, Dong-qi Zhang, Zhong Liao, Bin Wang, Suzhen Gong, Chuang Wang, Ming-zi Zhang, Guo-hua Wang, Huaibin Cai, Francesca-Fang Liao, Jiang-ping Xu
BACKGROUND: Compelling evidence suggests that inhibition of the complex I of the electron transport chain and elevated oxidative stress are the earliest events during the pathogenesis of Parkinson's disease (PD). Therefore, anti-oxidants, especially those from natural sources, hold good promise in treating PD as demonstrated mostly by the studies in rodent models. RESULTS: Herein, we determined if polydatin (piceid), a natural polyphenol, could exert anti-oxidative activity and attenuate dopaminergic neurodegeneration in three commonly used rodent models of PD...
2015: Molecular Neurodegeneration
https://www.readbyqxmd.com/read/25962878/dual-target-strategy-combining-distinct-non-dopaminergic-treatments-reduces-neuronal-cell-loss-and-synergistically-modulates-l-dopa-induced-rotational-behavior-in-a-rodent-model-of-parkinson-s-disease
#20
Marie-Therese Fuzzati-Armentero, Silvia Cerri, Giovanna Levandis, Giulia Ambrosi, Elena Montepeloso, Gianfilippo Antoninetti, Fabio Blandini, Younis Baqi, Christa E Müller, Rosaria Volpini, Giulia Costa, Nicola Simola, Annalisa Pinna
The glutamate metabotropic receptor 5 (mGluR5) and the adenosine A2A receptor (A2A R) represent major non-dopaminergic therapeutic targets in Parkinson's disease (PD) to improve motor symptoms and slow down/revert disease progression. The 6-hydroxydopamine rat model of PD was used to determine/compare the neuroprotective and behavioral impacts of single and combined administration of one mGluR5 antagonist, 2-methyl-6-(phenylethynyl)pyridine (MPEP), and two A2A R antagonists, (E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] (MSX-3) and 8-ethoxy-9-ethyladenine (ANR 94)...
August 2015: Journal of Neurochemistry
keyword
keyword
55861
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"